[admin]

Acute chest pain is one of the most common and clinically demanding presentations encountered in emergency and cardiology settings. Because chest pain can originate from myocardial injury, thromboembolic disease, heart failure, or non-cardiac causes, clinicians rely heavily on cardiac biomarkers to differentiate these possibilities quickly and safely. Nanjing Poclight Biotechnology Co., Ltd., operating under the brand Poclight, has developed a portfolio of homogeneous chemiluminescence immunoassay reagents and a compact instrument platform designed specifically to support this diagnostic process.

Understanding the Diagnostic Challenge of Acute Chest Pain

The core difficulty in assessing acute chest pain is that imaging-based confirmation—such as compression ultrasound or CT pulmonary angiography—is often required only after risk has been stratified through laboratory testing. According to the knowledge base, confirmed venous thromboembolism prevalence in suspected outpatients is 20% or less, meaning a large proportion of patients could be spared unnecessary imaging, contrast-induced nephropathy risk, and excess blood exposure if a reliable non-invasive triage tool were available. This is precisely the gap that cardiac and thrombosis biomarker testing is intended to fill.

The Role of Cardiac Biomarkers: Myocardial Injury Markers

For patients presenting with suspected acute myocardial infarction or acute coronary syndrome, Poclight offers three complementary myocardial injury markers—CK-MB, MYO, and hs-cTnT—each addressing a different phase or aspect of injury detection.

CK-MB functions as a cardiac marker for diagnosis of myocardial infarction when interpreted alongside clinical presentation and medical history. It is detectable 3–8 hours after cardiac symptom onset, though it is not specific for myocardial infarction on its own, so results require clinical context. Poclight’s CK-MB assay delivers a result in 5 minutes, uses only 50 uL of serum or plasma, and covers a measuring range of 0.3–300 ng/mL, with sex-specific expected values of ≤4.87 ng/mL for males and ≤3.61 ng/mL for females. Correlation data with Roche Elecsys CK-MB are provided in the source, supporting its use in stroke centers, cardiology departments, and intensive care units.

MYO (myoglobin) addresses the earliest phase of myocardial injury. As a small cytoplasmic protein of 17.8 kDa, myoglobin is released rapidly after myocardial injury, making it useful for diagnosis of acute myocardial infarction, early reinfarction, and assessment of successful reperfusion following lysis therapy. The assay also returns results in 5 minutes from a 50 uL sample, with a measuring range of 21–3000 ng/mL and sex-specific expected values of 28–72 ng/mL for males and 25–58 ng/mL for females. Correlation data with Roche Elecsys Myoglobin are included in the source material.

hs-cTnT, Poclight’s high-sensitivity cardiac troponin T assay, is positioned for early detection, dynamic monitoring, and risk stratification of myocardial injury—arguably the most clinically nuanced of the three markers. Acute chest pain in the emergency department requires rapid rule-out, yet interpretation must account for several confounders: chronic kidney disease patients have elevated baseline hs-cTnT, elderly patients may have occult coronary artery disease, and healthy males show higher baseline hs-cTnT than females. The assay’s limit of detection below 5 ng/L supports ESC 0/1h algorithms with greater than 99% negative predictive value for safe discharge decisions. It runs in 10 minutes, requires 200 uL of sample, and measures across 5–10,000 ng/L, with an expected value threshold of ≤14 ng/mL. Notably, the source data report an AUC of 0.852 for all-cause mortality prediction using hs-cTnT, compared with 0.811 for hs-cTnI—a difference of 0.041. In chronic kidney disease patients, distinguishing acute from chronic elevation depends on dynamic change, specifically a rise greater than 20% within 3 hours, while persistent elevation is associated with a 2.5–3.0-fold increase in cardiovascular mortality risk. Dynamic serial measurements of hs-cTnT also provide prognostic value for outcomes including heart failure and sudden cardiac death, extending its role beyond initial triage into ongoing risk stratification across emergency, cardiology, nephrology, oncology, ICU, and physical examination center settings.

Beyond the Heart: Excluding Venous Thromboembolism with D-Dimer

Chest pain is not always cardiac in origin, and pulmonary embolism remains an important differential diagnosis. Poclight’s D-Dimer Test Kits are positioned for rapid exclusion of venous thromboembolism when used together with a non-high or unlikely clinical probability assessment. Given that confirmed venous thromboembolism prevalence in suspected outpatients is 20% or less, a high-sensitivity, non-invasive D-dimer result can meaningfully reduce reliance on compression ultrasound or CT pulmonary angiography, thereby avoiding contrast-induced nephropathy risk. The assay is deliberately built for speed and low specimen demand: a 5-minute turnaround from just 50 uL of plasma, with a measuring range of 0.25–20 mg/L and an expected value below 0.5 mg/L. Its low specificity means exclusion should be restricted to patients assessed as non-high or unlikely probability, guiding clinicians toward appropriate use rather than blanket application.

Heart Failure Assessment with Natriuretic Peptides

When chest pain is accompanied by respiratory symptoms suggestive of congestive heart failure, Poclight’s BNP and NT-proBNP assays provide objective marker support for diagnosis and severity assessment. Both complete in 5 minutes; BNP requires 100 uL of plasma with a measuring range of 15–5000 pg/mL, while NT-proBNP uses 100 uL of serum or plasma across a wider range of 15–35,000 pg/mL. Method comparison data with another manufacturer are documented for BNP. Both markers are adapted for acute chest pain scenarios involving respiratory failure, heart failure, pulmonary embolism, aortic dissection, and acute myocardial infarction—reinforcing their relevance to the broader chest pain differential.

The Platform Behind the Biomarkers: C5000 Dry Micro System

All of these assays run on Poclight’s C5000 Dry Micro System, a portable, semi-automatic instrument built on a fifth-generation homogeneous chemiluminescence immunoassay platform. The system eliminates magnetic beads, complex liquid paths, and wash steps, delivering a first sample result in 3 minutes across 7 independent test positions, with throughput of 80 tests/hour and a coefficient of variation below 5%. Weighing no more than 8.5 kg, it supports touch-screen operation and LIS/HIS connectivity for real-time information sharing. Its lyophilized reagent format allows room-temperature storage and transport, removing cold-chain logistics constraints that typically complicate point-of-care deployment in stroke centers, cardiology departments, ICUs, emergency departments, nephrology, oncology, and physical examination centers.

Together, this integrated approach—combining myocardial injury markers, venous thromboembolism exclusion, heart failure assessment, and a rapid, portable testing platform—illustrates how cardiac biomarkers function as the analytical backbone of acute chest pain assessment, enabling faster triage and more informed risk stratification at the point of care.

http://www.poclight.com
Nanjing Poclight Biotechnology Co., Ltd

[Author]

Posts